The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management.
作者信息
Denault Marie-Helene, Ho Cheryl
机构信息
Department of Pneumologie, Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada.
Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada.
出版信息
Transl Cancer Res. 2023 Mar 31;12(3):680-683. doi: 10.21037/tcr-22-2843. Epub 2023 Feb 23.
Abstract
摘要
相似文献
1
The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management.疑罪从无：不可切除的III期非小细胞肺癌治疗中的程序性死亡受体配体1（PD-L1）状态
Transl Cancer Res. 2023 Mar 31;12(3):680-683. doi: 10.21037/tcr-22-2843. Epub 2023 Feb 23.
2
Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy.检测不可切除的 III 期非小细胞肺癌患者接受放化疗时使用 22C3 抗体的程序性细胞死亡配体 1。
Int J Clin Oncol. 2021 Apr;26(4):659-669. doi: 10.1007/s10147-020-01856-x. Epub 2021 Jan 7.
3
[Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].[程序性死亡蛋白1/程序性死亡配体1抑制剂治疗转移性非小细胞肺癌患者的疗效及预后预测生物标志物的真实世界研究]
Zhonghua Zhong Liu Za Zhi. 2022 May 23;44(5):416-424. doi: 10.3760/cma.j.cn112152-20210709-00504.
4
A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.使用克隆SP142抗体对非小细胞肺癌患者程序性细胞死亡配体-1表达的综合分析
Clin Lung Cancer. 2017 Sep;18(5):572-582.e1. doi: 10.1016/j.cllc.2017.02.004. Epub 2017 Mar 2.
5
PD-L1 expression is associated with advanced non-small cell lung cancer.程序性死亡受体配体1（PD-L1）表达与晚期非小细胞肺癌相关。
Oncol Lett. 2016 Aug;12(2):921-927. doi: 10.3892/ol.2016.4741. Epub 2016 Jun 16.
6
GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy.GEMSTONE-301：一项关于CS1001作为巩固治疗的III期临床试验，受试患者为局部晚期/不可切除（III期）非小细胞肺癌（NSCLC）患者，这些患者在先前的同步/序贯放化疗后未出现疾病进展。
Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015. doi: 10.21037/tlcr-20-608.
7
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.PD-1/PD-L1 阻断疗法在晚期非小细胞肺癌中的应用：现状与未来方向。
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
8
Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree?程序性细胞死亡配体-1（PD-L1）作为非小细胞肺癌（NSCLC）治疗的生物标志物——我们找错方向了吗？
Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S275-S279. doi: 10.21037/tlcr.2018.04.18.
9
Role of CTLA Inhibition in Management of Non-Small Cell Lung Cancer.CTLA-4 抑制剂在非小细胞肺癌治疗中的作用。
Curr Oncol Rep. 2022 Jan;24(1):113-123. doi: 10.1007/s11912-021-01164-1. Epub 2022 Jan 20.
10
Induction Immunotherapy Followed by Thoracic Radiation without Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Case Series.无法切除的 III 期非小细胞肺癌患者采用诱导免疫治疗联合胸部放疗而不进行化疗：病例系列研究。
Asian Pac J Cancer Prev. 2022 Jan 1;23(1):217-220. doi: 10.31557/APJCP.2022.23.1.217.
本文引用的文献
1
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.不可切除 III 期非小细胞肺癌患者在放化疗后接受度伐利尤单抗治疗的特点和真实世界无进展生存：PACIFIC-R 研究结果。
J Thorac Oncol. 2023 Feb;18(2):181-193. doi: 10.1016/j.jtho.2022.10.003. Epub 2022 Oct 25.
2
Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors.度伐利尤单抗巩固治疗 III 期非小细胞肺癌的疗效：关注治疗选择和预后因素。
Immunotherapy. 2022 Aug;14(12):927-944. doi: 10.2217/imt-2021-0341. Epub 2022 Jul 13.
3
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline.无驱动基因改变的IV期非小细胞肺癌的治疗：美国临床肿瘤学会生存指南
J Clin Oncol. 2022 Oct 1;40(28):3323-3343. doi: 10.1200/JCO.22.00825. Epub 2022 Jul 11.
4
Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches.不可切除的 III 期非小细胞肺癌的免疫治疗：现状和新的治疗方法。
Ann Oncol. 2022 Sep;33(9):893-908. doi: 10.1016/j.annonc.2022.06.013. Epub 2022 Jun 28.
5
Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab.PD-L1 表达在接受根治性放化疗和辅助 durvalumab 治疗的 III 期非小细胞肺癌中的预后和预测作用。
Int J Radiat Oncol Biol Phys. 2022 Jul 15;113(4):752-758. doi: 10.1016/j.ijrobp.2022.03.015. Epub 2022 Apr 19.
6
Consolidative durvalumab outcomes in stage III non-small cell lung cancer in a multi-centre study.多中心研究中 III 期非小细胞肺癌巩固性 durvalumab 治疗结果。
Cancer Treat Res Commun. 2021;29:100496. doi: 10.1016/j.ctarc.2021.100496. Epub 2021 Nov 27.
7
Tumor PD-L1 expression is associated with outcomes in stage III non-small cell lung cancer (NSCLC) patients treated with consolidation durvalumab.肿瘤程序性死亡受体配体1（PD-L1）表达与接受度伐鲁单抗巩固治疗的Ⅲ期非小细胞肺癌（NSCLC）患者的预后相关。
Transl Lung Cancer Res. 2021 Jul;10(7):3071-3078. doi: 10.21037/tlcr-21-249.
8
Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT).在随机、多中心、III 期德国肺癌协作组试验（GILT）中，同步放化疗治疗局部晚期 NSCLC 时 PD-L1 表达和肿瘤浸润淋巴细胞（TiLs）的预后和预测价值。
Lung Cancer. 2021 Oct;160:17-27. doi: 10.1016/j.lungcan.2021.07.008. Epub 2021 Jul 20.
9
The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures.程序性死亡配体1表达对早期切除的非小细胞肺癌预后的影响：文献的荟萃分析
Front Oncol. 2021 Feb 23;11:567978. doi: 10.3389/fonc.2021.567978. eCollection 2021.
10
Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy.不可切除的 III 期非小细胞肺癌患者接受放化疗时 PD-L1 表达的预后价值。
Radiat Oncol. 2020 Oct 29;15(1):247. doi: 10.1186/s13014-020-01696-z.
Zotero 插件